Revisiting Functional Dyspepsia Therapy: The Role of Itopride Hydrochloride

Abstract

Functional dyspepsia and gastroesophageal reflux disease (GERD) are common and often distressing gastrointestinal disorders that significantly affect patients’ quality of life and daily productivity. Among the available therapeutic options, itopride hydrochloride has emerged as a promising prokinetic agent because of its unique dual mechanism of action: dopamine D₂ receptor antagonism and acetylcholinesterase inhibition, which enhances gastrointestinal motility and accelerates gastric emptying. This review revisits the pharmacological profile, pharmacokinetics, clinical efficacy, safety, and cost-effectiveness of itopride in the management of functional dyspepsia, GERD, and related motility disorders. Evidence from clinical trials, including comparative studies with proton pump inhibitors and other prokinetics, highlights its effectiveness in improving symptoms such as bloating, early satiety, nausea, epigastric pain, and postprandial distress, with a favorable tolerability profile and minimal cardiac or central nervous system adverse effects. Additionally, pharmacoeconomic analyses suggest that itopride is a cost-effective treatment option in certain healthcare settings. Overall, itopride hydrochloride offers a balanced combination of efficacy, safety, and economic value, making it a valuable therapeutic choice in the management of upper gastrointestinal motility disorders. In addition to other benzamides, itopride increases colonic peristalsis and propels luminal contents, which may assist in the management of functional bowel problems.